References
- Dubois MF, Hébert R. The incidence of vascular dementia in Canada: a comparison with Europe and East Asia. Neuroepidemiology. 2001;20:179–87.
- Farkas E, Luiten PG, Bari F. Permanent bilateral common carotid artery occlusion in the rat: a model for chronic cerebral hypoperfusion-related neurodegenerative diseases. Brain Res Rev. 2007;54:162–80.
- Vicente E, Degerone D, Bohn L, Scornavaca F, Pimentel A, Leite MC, et al.. Astroglial and cognitive effects of chronic cerebral hypoperfusion in the rat. Brain Res. 2009;1251:204–12.
- Bruce-Keller AJ. Microglial–neuronal interactions in synaptic damage and recovery. J Neurosci Res. 1999;58:191–201.
- Tuppo EE, Arias HR. The role of inflammation in Alzheimer’s disease. Int J Biochem Cell Biol. 2005;37:289–305.
- Mrak RE, Griffin WS. The role of activated astrocytes and of the neurotrophic cytokine S100B in the pathogenesis of Alzheimer’s disease. Neurobiol Aging. 2001;22:915–22.
- Hu J, Van Eldik LJ. Glial-derived proteins activate cultured astrocytes and enhance β amyloid-induced glial activation. Brain Res. 1999;842:46–54.
- Ponath G, Schettler C, Kaestner F, Voigt B, Wentker D, Arolt V, et al.. Autocrine S100B effects on astrocytes are mediated via RAGE. J Neuroimmunol. 2007;184:214–22.
- Kim SH, Smith CJ, Van Eldik LJ. Importance of MAPK pathways for microglial pro-inflammatory cytokine IL-1β production. Neurobiol Aging. 2004;25:431–9.
- Hu J, Ferreira A, Van Eldik LJ. S100beta induces neuronal cell death through nitric oxide release from astrocytes. J Neurochem. 1997;69:2294–301.
- Lam AG, Koppal T, Akama KT, Guo L, Craft JM, Samy B, et al.. Mechanism of glial activation by S100B: involvement of the transcription factor NFkappaB. Neurobiol Aging. 2001;22:765–72.
- Yao WX, Jiang MX. Effects of tetrandrine on cardiovascular electrophysiologic properties. Acta Pharmacol Sin. 2002;23:1069–74.
- Wu SJ, Ng LT. Tetrandrine inhibits proinflammatory cytokines, iNOS and COX-2 expression in human monocytic cells. Biol Pharm Bull. 2007;30:59–62.
- Lin ST, Wang Y, Xue Y, Feng DC, Xu Y, Xu LY. Tetrandrine suppresses LPS-induced astrocyte activation via modulating IKKs-IkappaBalpha-NF-kappaB signaling pathway. Mol Cell Biochem. 2008;315:41–9.
- Lin TY, Tseng SH, Li SJ, Chen JC, Shieh JS, Chen Y. Tetrandrine increased the survival rate of mice with lipopolysaccharide-induced endotoxemia. J Trauma. 2009;66:411–7.
- He FQ, Qiu BY, Zhang XH, Li TK, Xie Q, Cui DJ, et al.. Tetrandrine attenuates spatial memory impairment and hippocampal neuroinflammation via inhibiting NF-κB activation in a rat model of Alzheimer’s disease induced by amyliod-β (1–42). Brain Res. 2011;1384:89–96.
- Pappas BA, de la Torre JC, Davidson CM, Keyes MT, Fortin T. Chronic reduction of cerebral blood flow in the adult rat: late-emerging CA1 cell loss and memory dysfunction. Brain Res. 1996;708:50–8.
- Zhu LX, Dong Z, Liao H, He BC, Xiao YL. An experimental study on rats brain protection of tetrandrine from dementia (in Chinese). Chin Pharmacol Bull. 2004;20:959–60.
- Morris R.G. Developments of a water maze procedure for studying spatial learning in the rat. J Neurosci Methods. 1984;11:47–60.
- Zarow C, Vinters HV, Ellis WG, Weiner MW, Mungas D, White L, et al.. Correlates of hippocampal neuron number in Alzheimer’s disease and ischemic vascular dementia. Ann Neurol. 2005;57:896–903.
- Zhu LX, Dong Z, Liao H. The experimental study on protective effect of tetrandrine on rat’s dementia induced by QA (in Chinese). Chin J Gerontol. 2005;25:78–80.
- Takano T, Tian GF, Peng W, Lou N, Libionka W, Han X, et al.. Astrocyte-mediated control of cerebral blood flow. Nat Neurosci. 2006;9:260–7.
- Engelhart MJ, Geerlings MI, Meijer J, Kiliaan A, Ruitenberg A, van Swieten JC, et al.. Inflammatory proteins in plasma and the risk of dementia: the Rotterdam study. Arch Neurol. 2004;61:668–72.
- Yamasaki Y, Matsuura N, Shozuhara H, Onodera H, Itoyama Y, Kogure K. Interleukin-1 as a pathogenetic mediator of ischemic brain injury in rats. Stroke. 1995;26:676–81.
- Barone FC, Arvin B, White RF, Miller A, Webb CL, Willette RN, et al.. Tumor necrosis factor-alpha. A mediator of focal ischemic brain injury. Stroke. 1997;28:1233–44.
- Mori T, Town T, Kobayashi M, Tan J, Fujita SC, Asano T, et al.. Augmented delayed infarct expansion and reactive astrocytosis after permanent focal ischemia in apolipoprotein E4 knock-in mice. J Cereb Blood Flow Metab. 2004;24:646–56.
- Mori T, Tan J, Arendash GW, Koyama N, Nojima Y, Town T. Overexpression of human S100B exacerbates brain damage and periinfarct gliosis after permanent focal ischemia. Stroke. 2008;39:2114–21.
- Mori T, Koyama N, Arendash GW, Horikoshi-Sakuraba Y, Tan J, Town T. Overexpression of human S100B exacerbates cerebral amyloidosis and gliosis in the Tg2576 mouse model of Alzheimer’s disease. Glia. 2010;58:300–14.
- Asano T, Mori T, Shimoda T, Shinagawa R, Satoh S, Yada N, et al.. Arundic acid (ONO-2506) ameliorates delayed ischemic brain damage by preventing astrocytic overproduction of S100B. Curr Drug Targets CNS Neurol Disord. 2005;4:127–42.
- Mori T, Town T, Tan J, Yada N, Horikoshi Y, Yamamoto J, et al.. Arundic Acid ameliorates cerebral amyloidosis and gliosis in Alzheimer transgenic mice. J Pharmacol Exp Ther. 2006;318:571–8.
- Donato R. RAGE: a single receptor for several ligands and different cellular responses: the case of certain S100 proteins. Curr Mol Med. 1997;7:711–24.
- Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, et al.. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell. 1999;97: 889–901.
- Bianchi R, Giambanco I, Donato R. S100B/RAGE dependent activation of microglia via NF-kappaB and AP-1 Coregulation of COX-2 expression by S100B, IL-1beta and TNF-alpha. Neurobiol Aging. 2010;31:665–77.
- Hu J, Castets F, Guevara JL, Van Eldik LJ. S100beta stimulates inducible nitric oxide synthase activity and mRNA levels in rat cortical astrocytes. J Biol Chem. 1996;271:2543–7.